Regulatory Affairs Professionals Society
Press release/News aggregator
The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Founded in 1976, RAPS helped establish the regulatory profession and continues to actively support the professional and lead the profession as a neutral, non-lobbying nonprofit organization. RAPS offers education and training, professional standards, publications, research, knowledge sharing, networking, career development opportunities and other valuable resources, including Regulatory Affairs Certification (RAC) credentials, the only post-academic professional certifications to recognize regulatory excellence. RAPS is headquartered in suburban Washington, DC, with chapters and affiliates worldwide. Source
Actions
Media Outlet details
| Scope | N/A |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesQuebec Local Networking Group Virtual Event: RIM - The data foundation your compliance strategy depends on
In our last session on XaaS and AI, we presented an approach for implementing cloud and AI technologies in regulated environments. The natural next question is: where does an organization begin? For regulatory affairs professionals, the answer comes back to one thing: how well your regulatory information is structured and managed. In this session, we will explore a system built with this exact objective in mind: the Regulatory Information Management (RIM) system.
US FDA warns drugmakers in India, China and the US for GMP issues
US FDA warns drugmakers in India, China and the US for GMP issues Historical FDA badges. (Photo: Ferdous Al-Faruque) The US Food and Drug Administration (FDA) recently sent warning letters to companies in China, India, and the US for multiple violations of good manufacturing practices (GMP) related to the production of active pharmaceutical ingredients (APIs) and finished drugs.
FDA drafts guidance on assessing potency of immunotherapy products
FDA drafts guidance on assessing potency of immunotherapy products Source: iStock The US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) has issued a guidance to assist sponsors in assessing potency assays for active immunotherapy products (ACTIMPs), including cancer vaccines and treatments for autoimmune diseases.
FDA warns drugmakers in India, China and the US for GMP issues
FDA warns drugmakers in India, China and the US for GMP issues Historical FDA investigator badges. (Photo: Ferdous Al-Faruque) The US Food and Drug Administration (FDA) recently sent warning letters to companies in China, India, and the US for multiple violations of good manufacturing practices (GMP) related to the production of active pharmaceutical ingredients (APIs) and finished drugs.
Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves
Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
Brazil Local Networking Group In Person Event: Mesa Redonda: Regulatory Leaders Speak O Futuro da Liderança em Assuntos Regulatórios
Este evento será realizado em português do Brasil. Mesa redonda com a participação de líderes da área de Assuntos Regulatórios de medicamentos e produtos para saúde para discussão de como a liderança pode se preparar para os desafios futuros. Localização Questions Contact the RAPS Support Center: Call +1 301 770 2920, ext. 200 (8:30 am–5:30 pm EST, Monday–Friday) or email Speakers
FDA seeks feedback on framework for regulating GenAI devices
FDA seeks feedback on framework for regulating GenAI devices Source: iStock The US Food and Drug Administration (FDA) is seeking feedback on a competency-based approach to regulating medical devices that utilize generative artificial intelligence (GenAI). This proposal was introduced in a discussion paper in which the agency seeks feedback on its proposed approach.
Therapeutic equivalence: FDA finalizes guidance on TE evaluations
Therapeutic equivalence: FDA finalizes guidance on TE evaluations FDA headquarters in White Oak, Md. (Photo: Ferdous Al-Faruque) The US Food and Drug Administration (FDA) on Monday finalized guidance on its approach to making therapeutic equivalence (TE) evaluations and assigning therapeutic equivalence (TE) codes for abbreviated new drug applications (ANDAs). These codes are listed in the agency’s Orange Book and denote a drug’s bioequivalence to a reference-listed drug (RLD).
Asia-Pacific Roundup: TGA seeks feedback on automated decision making for changes to listed medicines
Asia-Pacific Roundup: TGA seeks feedback on automated decision making for changes to listed medicines Australia’s Therapeutic Goods Administration (TGA) has started a consultation into proposed changes to support automated decision making (ADM) for listed medicine variation applications. Under Australian legislation, listed medicines are included in the Australian Register of Therapeutic Goods (ARTG) without pre-market assessment by TGA.
Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again
Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.